PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its financial results for the fourth quarter and full ...

Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials ...

Palvella Therapeutics, Inc. (Nasdaq: PVLA) will take center stage at the 15th World Congress of Pediatric Dermatology in ...

EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations ...

Differential Response Between African Americans and Non-African Americans with Resistant Hypertension to MANP, a Novel ...

today announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a late-breaking presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference ...

The role of AI in supply chain management proved to be the focal issue at the recent 2025 Clinical Trial Supply Europe ...

The oral presentation from the LUCE-1 clinical trial in Usher 1B builds on the data presented at the FLORetina medical conference in December 2024 with updates from more patients dosed since then, and ...

The oral presentation from the LUCE-1 clinical trial in Usher 1B builds on the data presented at the FLORetina medical conference in December 2024 with updates from more patients dosed since then ...

Panelists discuss the presentation and management of a case involving HER2-mutated metastatic non–-small cell lung cancer ...